Mark Blagden

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

Eugène McCloskey, J. Rathi, S. Heijmans et al. · Osteoporosis International · 2020 · 158 citations · Full text

Medicine, Family Medicine, Geriatric Medicine +16